Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Eli Lilly and Company regarding potential securities fraud related to misleading statements about the phase 3 trial results of their weight loss drug, Orforglipron [1][3]. Group 1: Investigation Details - The investigation focuses on whether Eli Lilly misled investors about the expected results of the phase 3 trial for Orforglipron, where patients experienced an average of 11.5% placebo-adjusted weight loss over 72 weeks, significantly lower than the 15% projected by analysts [3]. - Additionally, the trial saw a dropout rate of 10.3% for patients on the highest dose of Orforglipron due to side effects, compared to only 2.6% for those on a placebo, raising concerns about the drug's safety and efficacy claims [3]. Group 2: Investor Actions - Investors who suffered losses are encouraged to contact attorney Lesley F. Portnoy for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2][4]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing, indicating a strong track record in pursuing such claims [4].